Skip to content
AnalystLens

James Hardie Industries 8-K Report (Oct 17, 2025)

Filing Date
Filed October 17, 2025
Period End
October 17, 2025
Securities
JHXJHIUF
In the record · 2016–202610-K1210-Q28-K402

JHX filed 12 annual reports (10-K), 2 quarterly reports (10-Q) and 402 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Oct ’26Oct ’26

Summary

Summary of the 6-K filed October 17, 2025. Cited figures are marked; the original filing is the authoritative source.

This Form 6-K from James Hardie Industries plc (JHX) filed on October 17, 2025 consists mainly of ASX and Irish regulatory notices rather than financial results or operating updates.

The forward-looking statements cover the AZEK acquisition, asbestos-related AICF contributions, tax matters and economic conditions, but the filing states no new financial figures for the company itself. The most notable item is a substantial holding notice (Exhibit 99.1) reporting that FMR LLC's voting-rights position in the company crossed below the 3%a threshold on October 3, 2025. The filing shows FMR LLC holding 2.7133% of voting rights (15,715,027 voting rights) against 579,185,043 total voting rights, down from a previous notified position of 3.0502%.

The notice attributes the change to a stock merger after M&A completion, referring to the AZEK transaction. The remaining exhibits are ASX listing forms (Appendix 3G and Appendix 2A) covering the issue and quotation of ordinary shares and CDIs. These include shares issued in 2025 to settle certain AZEK equity awards following the July 1, 2025 merger, and CDIs issued under an employee incentive scheme, with the filing showing the issue prices in US dollars and the resulting share counts.

Key Highlights

  1. FMR LLC's holding fell below the 3% threshold on October 3, 2025, to 2.7133% of voting rights (15,715,027 voting rights), from a previous notified 3.0502%.
  2. Total voting rights in James Hardie Industries plc are stated as 579,185,043 in the substantial holding notice.
  3. The AZEK merger closed on July 1, 2025; ordinary shares were issued in respect of settling certain AZEK equity awards outstanding at closing.
  4. Appendix 3G notices report 12,486 ordinary shares issued October 1, 2025 at USD 0.6938 and 1,043 ordinary shares issued October 2, 2025 at USD 0.69.
  5. An updated Appendix 2A corrects that no JHXAM shares were transferred to CDIs; instead 716 new CDIs were issued.
  6. Applications for quotation cover 54,757 CDIs issued October 3, 2025 at USD 0.6938 and 120 CDIs issued October 10, 2025 at USD 19.244, both under an employee incentive scheme.
  7. Post-issuance, the filing shows 430,076,412 CDIs quoted on ASX, alongside 4,670,265 restricted stock units and 149,177,753 unquoted ordinary shares.

Frequently Asked Questions

  1. Why did FMR LLC's reported holding change?

    The substantial holding notice states that FMR LLC's voting-rights position crossed below the 3% threshold on October 3, 2025, with the reason given as a stock merger after M&A completion. The notified holding was 2.7133%, compared with a previous notification of 3.0502%.

  2. What do the share issuances in this filing relate to?

    The Appendix 3G notices state that the ordinary shares were issued in respect of the settlement of certain AZEK equity awards outstanding as of the closing of the merger on July 1, 2025. The filing also reports smaller issuances under an employee incentive scheme.

  3. Does this filing include financial results or guidance?

    No. The filing contains regulatory notices and listing forms. Its forward-looking statements list the risks and matters relevant to the company's business, including the AZEK acquisition, AICF contributions and tax matters, but it does not report new financial results or guidance.

  4. What number of CDIs and shares does the company have after these issuances?

    The most recent Appendix 2A in the filing reports 430,076,412 CDIs quoted on ASX, 4,670,265 restricted stock units, 149,177,753 unquoted ordinary shares and 269,221 options expiring November 3, 2027 at an exercise price of USD 33.05.